Current Report Filing (8-k)
November 02 2017 - 4:15PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 2, 2017 (October 30, 2017)
Date
of
Report
(Date
of
earliest
event
reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
WYOMING
|
000-55364
|
36-4787690
|
(State or other jurisdiction of
|
(Commission
|
(I.R.S. Employer
|
incorporation or organization)
|
File Number)
|
Identification No.)
|
(Exact name
of
registrant as
specified
in
charter)
642 Newtown Yardley Road Suite 100
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (215) 944-6100
Check
the
appropriate
box
below
if
the
Form
8-K
filing
is
intended
to
simultaneously
satisfy
the
filing
obligation
of
the
registrant
under
any
of
the
following
provisions:
|
☐
|
Written
communications
pursuant
to
Rule
425
under
the
Securities
Act
(17
CFR
230.425)
|
|
☐
|
Soliciting
material
pursuant
to
Rule
14a12
under
the
Exchange
Act
(17
CFR
240.14a12)
|
|
☐
|
Precommencement
communications
pursuant
to
Rule
14d2(b)
under
the
Exchange
Act
(17
CFR
240.14d2(b))
|
|
☐
|
Precommencement
communications
pursuant
to
Rule
13e4(c)
under
the
Exchange
Act
(17
CFR
240.13e4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company
☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
☑
1
Item 1.01
|
Entry into a Material Definitive Agreement
|
On October 30, 2017, NeuroHabilitation Corporation (“NHC”), a subsidiary of Helius Medical Technologies, Inc. (the “Company” or “Helius”) executed an amendment to the asset purchase agreement entered into with A&B(HK) Company, Limited, dated as of October 9, 2015. The amendment extends the deadline to satisfy NHC’s obligations under the Cooperative Research and Development Agreement (the “CRADA”) framework with the United States Army to obtain FDA marketing authorization for commercialization of or otherwise ensure that the PoNS™ device is available for purchase by the U.S. Government to December 31, 2021. As previously reported, the Company amended the CRADA on September 6, 2017 to extend the expiration date of the CRADA to December 31, 2018 and to extend the deadline for commercialization of the PoNS™ device to December 31, 2021. The preceding summary of the amendment is qualified in its entirety by reference to Amendment to Asset Purchase Agreement which is attached hereto as Exhibit 10.1 and Asset Purchase Agreement between the Company and A&B (HK) Company Limited (filed as Exhibit 2.1 to the Form 8-K filed on October 16, 2015).
Item 9.01.
Financi
al Statements and Exhibits.
(d) Exhibits
2
SIGNATURE
Pursuant
to
the
requirements
of
the
Securities
Exchange
Act
of
1934,
the
registrant
has
duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized
.
|
HELIUS MEDICAL TECHNOLOGIES, INC.
|
|
|
|
Dated: November 2, 2017
|
By:
|
/s/ Joyce LaViscount
|
|
|
Joyce LaViscount, Chief Financial Officer
|
|
|
3
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024